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MaBACKGROUND Elevated lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS). Oxidized phospholipids (OxPL)
are key mediators of calciﬁcation in valvular cells and are carried by Lp(a).
OBJECTIVES This study sought to determine whether Lp(a) and OxPL are associated with hemodynamic progression
of AS and AS-related events.
METHODS OxPL on apolipoprotein B-100 (OxPL-apoB), which reﬂects the biological activity of Lp(a), and Lp(a) levels
were measured in 220 patients with mild-to-moderate AS. The primary endpoint was the progression rate of AS,
measured by the annualized increase in peak aortic jet velocity in m/s/year by Doppler echocardiography; the secondary
endpoint was need for aortic valve replacement and cardiac death during 3.5  1.2 years of follow-up.
RESULTS AS progression was faster in patients in the top tertiles of Lp(a) (peak aortic jet velocity: þ0.26  0.26 vs.
þ0.17  0.21 m/s/year; p ¼ 0.005) and OxPL-apoB (þ0.26  0.26 m/s/year vs. þ0.17  0.21 m/s/year; p ¼ 0.01). After
multivariable adjustment, elevated Lp(a) or OxPL-apoB levels remained independent predictors of faster AS progression.
After adjustment for age, sex, and baseline AS severity, patients in the top tertile of Lp(a) or OxPL-apoB had increased
risk of aortic valve replacement and cardiac death.
CONCLUSIONS Elevated Lp(a) and OxPL-apoB levels are associated with faster AS progression and need for aortic
valve replacement. These ﬁndings support the hypothesis that Lp(a) mediates AS progression through its associated
OxPL and provide a rationale for randomized trials of Lp(a)-lowering and OxPL-apoB-lowering therapies in AS.
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1237AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
AVR = aortic valve
replacement
CI = conﬁdence interval
LDL = low-density lipoproteinA ortic stenosis (AS), the most common form ofvalve disease in the western world, afﬂicts >1million individuals in North America (1).
Medical therapy to prevent development or reduce
progression of AS is currently not available, and aortic
valve replacement (AVR) remains the sole option
available for the treatment of severe symptomatic
AS (2,3).SEE PAGE 1247
LDL-C = low-density
lipoprotein cholesterol
Lp-PLA2 = lipoprotein-
associated phospholipase A2
Lp(a) = lipoprotein(a)
LPC = lysophosphatidylcholine
OR = odds ratio
OxPL = oxidized phospholipids
OxPL-apo(a) = oxidized
phospholipids on
apolipoprotein(a)
OxPL-apoB = oxidized
phospholipids on
apolipoprotein B-100
V = peak aortic jet velocityMendelian randomization analyses have identiﬁed
the single-nucleotide polymorphism rs10455872 at
the LPA locus as the only genome-wide signiﬁcant
single-nucleotide polymorphism associated with the
presence of aortic valve calciﬁcation (4). Rs10455872
segregates with smaller numbers of kringle (K)IV2
repeats in the LPA gene, which are inversely associ-
ated with lipoprotein(a) (Lp[a]) plasma levels. How-
ever, rs10455872 is associated with signiﬁcantly
elevated plasma Lp(a) levels beyond what would be
predicted from the relationship of KIV repeats alone
(5). Subsequent studies have validated these ﬁndings
and also reported an association between elevated
plasma Lp(a) levels and a higher prevalence of AS and
need for AVR in the general population (6,7). It has
not yet been established if elevated levels of Lp(a)
predict progression of pre-existing AS.
Oxidized phospholipids (OxPL) are proinﬂamma-
tory and proatherogenic (8). We developed an
immunoassay that measures the content of OxPL per
apolipoprotein B-100 (OxPL-apoB) and found that
Lp(a) was the major lipoprotein carrier of OxPL (9,10).
A large body of experimental and clinical studies
was generated with this assay to support a patho-
logical role of proinﬂammatory OxPL in mediating
anatomic cardiovascular disease, myocardial infarc-
tion, stroke, peripheral arterial disease, and risk of
cardiac death (11–13).
Experimental studies have reported the presence
of oxidized low-density lipoprotein (LDL), which is
enriched in OxPL, in aortic valves explanted from
surgery and suggested that it is directly involved in
pathophysiological processes leading to AS develop-
ment (14–17). Recently, the enzyme lipoprotein-
associated phospholipase A2 (Lp-PLA2), which uses
OxPL as a substrate to generate a free fatty acid and
lysophosphatidylcholine (LPC), was shown to be
highly expressed in stenotic aortic valves and was
involved in the mineralization process of valvular
interstitial cells via the production of LPC (18).
The plasma level of Lp-PLA2 was also associated
with a faster progression rate in patients with
mild AS at baseline (19). In addition, experimentalstudies have identiﬁed OxPL as key media-
tors of osteogenic differentiation and calciﬁ-
cation in vascular cells (20). These ﬁndings
support a role for an Lp(a)/OxPL/LPC
pathway in AS development and progression
(21).
A unifying hypothesis can be proposed
that Lp(a) mediates AS through its content of
OxPL. In this analysis of the ASTRONOMER
(Aortic Stenosis Progression Observation:
Measuring Effects of Rosuvastatin) trial, we
tested the hypothesis that Lp(a) and OxPL-
apoB are associated with hemodynamic pro-
gression of AS and AS-related events.
METHODS
The design of the ASTRONOMER trial
(NCT00800800) has been previously reported
(22). In brief, ASTRONOMER included 269
patients (age: 18 to 82 years) with mild-to-
moderate AS at baseline (peak aortic jet
velocity [Vpeak] ¼ 2.5 to 4.0 m/s) recruited in 23 Cana-
dian sites between 2002 and 2005. Exclusion criteria
were severe or symptomatic AS, severe aortic regur-
gitation, signiﬁcant mitral valve disease (mitral
stenosis or regurgitation), symptomatic coronary
artery disease, congestive heart failure, diabetes, or
need for low-density lipoprotein cholesterol (LDL-C)-
lowering treatment. Patients were randomized to
rosuvastatin, 40 mg versus placebo. The study proto-
col was approved by the institutional review boards at
all participating centers, and patients gave written
signed informed consent.
Clinical and Doppler echocardiographic data were
previously described (Online Appendix) (23). The
primary echocardiographic parameter to assess AS
severity was Vpeak. Aortic valve area was also derived
from the primary echocardiographic measurements;
because the ﬁndings are similar to Vpeak, the results
are in the Online Appendix.
Fasting plasma samples were collected and stored
at —80C. Plasma levels of glucose, creatinine, total
cholesterol, LDL-C, high-density lipoprotein choles-
terol, triglycerides, and apoB were measured using
automated techniques standardized with the Cana-
dian reference laboratory. LDL-C was corrected for
the cholesterol content in Lp(a) using the following
formula: corrected LDL-C ¼ LDL-C – Lp(a) mass in
mg/dl  0.3 (24). OxPL-apoB, OxPL on apolipopro-
tein(a) (OxPL-apo(a)), and Lp(a) were measured with
chemiluminescent immunoassays (Online Appendix)
as previously described (10,11,25,26). Forty-nine
peak
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1238(18.0%) patients were excluded from the current
analysis because of lack of plasma samples, leaving
220 patients (82.0%) for the measurement of OxPL-
apoB, OxPL-apo(a), and Lp(a) plasma levels. These
patients had similar baseline clinical and Doppler
echocardiographic characteristics compared with
those without OxPL-apoB, OxPL-apo(a), and Lp(a)
measurements. Because OxPL-apoB and OxPL-apo(a)
gave very similar results, data from OxPL-apo(a)
assay also are in the Online Appendix.
STUDY OUTCOMES. The primary outcome variable
was the progression rate of valve stenosis measured
as annualized changes in Vpeak. To account for
different follow-up lengths, annualized changes in
Vpeak were calculated by dividing the difference
between last follow-up and baseline values by the
length of follow-up. The secondary outcome was the
composite of AVR or cardiac death.
STATISTICAL ANALYSIS. Continuous data were
expressed as mean  SD and were tested for
normality of distribution and homogeneity of vari-
ances with the Shapiro-Wilk and Levene tests,
respectively. Lp(a) and OxPL-apoB plasma levels
were reported as median (interquartile range).
Continuous data were compared with the unpaired
Student t test across tertiles of Lp(a) and OxPL-apoB.
Categorical data were expressed as percentage and
compared across tertiles of Lp(a) and OxPL-apoB with
the chi-square or Fisher exact tests as appropriate.
Multivariable linear regression analyses were per-
formed to identify the independent predictors of AS
progression as annualized progression rates of Vpeak,
and results were reported as standardized raw-score
regression coefﬁcient (beta coefﬁcient)  SE. The
multivariable model included the following variables:
1) variables with a p value < 0.10 in individual anal-
ysis; 2) traditional cardiovascular risk factors; 3)
aortic valve phenotype (bicuspid vs. tricuspid); and 4)
randomization status (statin vs. placebo) (23). Lp(a)
and OxPL-apoB levels were not included in the
same model because of the important overlap be-
tween tertiles. Univariable and multivariable logistic
regression models were performed to identify the risk
of being rapid progressors, deﬁned as an annualized
progression rate of Vpeak $0.20 m/s/year as previ-
ously described (27). Results were reported as odds
ratios (OR) with 95% conﬁdence intervals (CI). Two-
way analyses of variance followed by Tukey post-
hoc tests were used to evaluate the effect of Lp(a) or
OxPL-apoB in the top tertiles and age, aortic valve
phenotype, or randomization status on stenosis pro-
gression rate. Two-way analyses of variance for
repeated measures followed by Tukey post-hoc testswere used to determine the effect of treatment and
time (baseline vs. 1-year follow-up) on Lp(a) and
OxPL-apoB levels. Kaplan-Meier curves of the time-
to-event data were used to assess the effect of Lp(a)
or OxPL-apoB in the top tertile on the composite of
AVR or cardiac death. Multivariable Cox proportional
hazards models adjusted for age, sex, and baseline AS
severity were performed to assess the independent
association between Lp(a) or OxPL-apoB in the top
tertile and the composite of AVR or cardiac death, and
results were reported as hazard ratios with 95% CI.
Adjusted Kaplan-Meier curves were generated from
the adjusted survival function obtained following Cox
models. A p value <0.05 was considered statistically
signiﬁcant.
RESULTS
POPULATION CHARACTERISTICS. Baseline clinical,
laboratory, and Doppler echocardiographic charac-
teristics are presented (Table 1) according to
top tertile of Lp(a) (>58.5 mg/dl) and OxPL-apoB
(>5.50 nM) versus middle and bottom tertiles
(Lp[a] #58.5 mg/dl and OxPL-apoB #5.50 nM). In the
overall group, median Lp(a) levels were 29.8 mg/dl
(12.1 to 76.1 mg/dl) and median OxPL-apoB levels
were 3.47 nM (2.26 to 8.64 nM). Eighty-one (37.0%)
patients had Lp(a) levels >50 mg/dl. Plasma levels of
Lp(a) and OxPL-apoB were strongly correlated (r ¼
0.86; p < 0.0001). Only 3 patients in the top tertile
of Lp(a) were in the middle or bottom tertiles of
OxPL-apoB, and 3 patients in the top tertile of OxPL-
apoB were in the middle or bottom tertiles of Lp(a).
Patients in top Lp(a) or OxPL-apoB tertiles had
similar clinical characteristics compared with patients
with lower Lp(a) or OxPL-apoB, but had lower LDL-C
corrected for Lp(a) cholesterol. The prevalence of
bicuspid aortic valve phenotype and hemodynamic AS
severity were similar between tertiles. The AV calciﬁ-
cation score assessed by echocardiography was signif-
icantly higher in the top OxPL-apoB tertile (Table 1).
Lp(a), OxPL, AND AS PROGRESSION. During the
mean follow-up of 3.5  1.2 years, patients in the top
Lp(a) or OxPL-apoB tertiles had signiﬁcantly faster
stenosis progression compared with those in the mid-
dle and bottom tertiles (Lp[a]: þ0.26  0.26
m/s/year vs. þ0.17  0.21 m/s/year; p ¼ 0.005)
(Figure 1A) (OxPL-apoB: þ0.26  0.26 m/s/year
vs. þ0.17  0.21 m/s/year; p ¼ 0.01) (Figure 1B). More-
over, patients in the middle tertile of Lp(a) and OxPL-
apoB had a similar progression rate compared with
those in the bottom tertile (Lp[a]:þ0.170.21m/s/year
vs. þ0.17  0.21 m/s/year; p ¼ 0.98) (OxPL-apoB: þ0.15
 0.21 m/s/year vs. þ0.19  0.21 m/s/year; p ¼ 0.51).
TABLE 1 Baseline Patient Characteristics
All Patients
(n ¼ 220)
Lp(a) Plasma Levels OxPL-apoB Plasma Levels
#58.5 mg/dl
Tertiles 1 and 2
(n ¼ 147; 67%)
>58.5 mg/dl
Tertile 3
(n ¼ 73; 33%) p Value
#5.50 nM
Tertiles 1 and 2
(n ¼ 147; 67%)
>5.50 nM
Tertile 3
(n ¼ 73; 33%) p Value
Clinical
Age, yrs 58  13 57  14 59  12 0.36 57  14 59  12 0.36
Male 60 61 59 0.82 61 59 0.82
Height, cm 169  10 169  9 170  10 0.28 169  9 170  10 0.38
Weight, kg 81  17 82  17 79  15 0.20 81  17 80  15 0.60
Body surface area, m2 1.91  0.21 1.91  0.21 1.90  0.22 0.63 1.91  0.21 1.91  0.21 0.99
Body mass index, kg/m2 28  6 29  6 27  4 0.03 28  6 28  4 0.26
Waist circumference, cm 95  14 95  14 94  12 0.44 95  14 95  13 0.86
Metabolic syndrome 27 29 22 0.28 29 22 0.28
History of hypertension 32 30 36 0.39 29 38 0.14
Systolic BP, mm Hg 127  17 128  18 125  14 0.19 128  18 125  15 0.32
Diastolic BP, mm Hg 75  10 76  10 74  11 0.14 76  10 75  10 0.45
History of smoking 46 51 45 0.42 50 47 0.60
Medication
Antihypertensive treatment 18 18 18 0.98 17 19 0.69
ACE inhibitors 10 10 11 0.86 10 12 0.52
ARBs 7 7 7 0.87 7 7 0.87
Rosuvastatin 51 49 55 0.42 50 53 0.60
Laboratory data
LDL-C, mg/dl 126  27 123  26 132  30 0.03 124  25 130  31 0.11
Corrected LDL-C, mg/dl 116  27 120  26 108  28 0.001 121  25 106  29 0.0001
apoB, mg/dl 102  19 100  17 105  20 0.04 100  17 106  21 0.10
HDL-C, mg/dl 57  16 56  16 61  18 0.02 56  16 61  18 0.02
Triglycerides, mg/dl 120  60 120  60 119  62 0.76 121  59 117  63 0.66
Fasting glucose, mg/dl 95  11 95  12 93  9 0.21 95  12 94  9 0.31
Creatinine, mg/dl 0.91  0.19 0.92  0.18 0.89  0.20 0.37 0.91  0.18 0.90  0.20 0.49
Lp(a), mg/dl 29.8 (12.1–76.1) 18.3 (8.8–29.9) 89.1 (76.3–104.5) — 18.3 (8.8–29.9) 89.1 (76.3–104.5) <0.0001
OxPL-apoB, nM 3.47 (2.26–8.64) 2.46 (1.97–3.50) 10.62 (8.61–15.40) <0.0001 2.46 (1.97–3.50) 10.62 (8.67–15.40) —
Doppler echocardiographic data
Bicuspid aortic valve 48 46 51 0.54 46 52 0.37
Aortic valve calciﬁcation score 1.7  0.7 1.7  0.7 1.8  0.6 0.08 1.6  0.7 1.9  0.6 0.03
Peak aortic jet velocity, m/s 3.2  0.4 3.2  0.4 3.1  0.4 0.08 3.2  0.4 3.1  0.4 0.09
Peak transvalvular gradient, mm Hg 41  11 42  11 39  10 0.08 42  11 39  10 0.08
Mean transvalvular gradient, mm Hg 22  7 23  7 22  7 0.27 23  7 22  7 0.22
Aortic valve area, cm2 1.34  0.42 1.35  0.42 1.32  0.41 0.62 1.35  0.42 1.32  0.41 0.69
Indexed aortic valve area, cm2/m2 0.70  0.20 0.71  0.21 0.69  0.19 0.71 0.71  0.21 0.69  0.19 0.65
Valvuloarterial impedance, mm Hg/ml$m2.04 4.9  1.5 4.9  1.6 4.9  1.1 0.99 4.9  1.6 4.8  1.1 0.94
Relative wall thickness ratio 0.44  0.09 0.44  0.09 0.43  0.08 0.68 0.44  0.10 0.43  0.08 0.56
LV mass index, g/m2.7 48  15 49  15 46  13 0.17 49  15 46  13 0.22
LV ejection fraction, % 66  6 65  6 67  8 0.15 65  6 67  7 0.12
Values are mean  SD, %, or median (interquartile range). LDL-C was corrected for the cholesterol content in Lp(a) using the following formula: corrected LDL-C ¼ LDL-C – Lp(a) mass in
mg/dl  0.3 (24).
ACE ¼ angiotensin-converting enzyme; apoB ¼ apolipoprotein B; ARB ¼ angiotensin receptor blocker; BP ¼ blood pressure; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein
cholesterol; Lp(a) ¼ lipoprotein(a); LV ¼ left ventricular; OxPL-apoB ¼ oxidized phospholipids on apolipoprotein B-100.
J A C C V O L . 6 6 , N O . 1 1 , 2 0 1 5 Capoulade et al.
S E P T E M B E R 1 5 , 2 0 1 5 : 1 2 3 6 – 4 6 OxPL, Lp(a), and AS Progression
1239On multivariable analyses adjusted for age, sex,
hypertension, smoking history, metabolic syndrome,
systolic blood pressure, statin use, corrected LDL-C,
apoB, creatinine, bicuspid aortic valve phenotype,
aortic valve calciﬁcation score, baseline Vpeak, and
valvuloarterial impedance, both top tertiles of Lp(a)
(beta coefﬁcient: 0.21  0.04; p ¼ 0.01) or OxPL-apoB
(beta coefﬁcient: 0.21  0.04; p ¼ 0.02) remainedindependent predictors of faster progression rate
assessed by Vpeak.
Patients in the top tertile of Lp(a) (OR: 2.1; 95% CI:
1.2 to 3.8; p ¼ 0.009) or OxPL-apoB (OR: 2.0; 95% CI:
1.1 to 3.5; p ¼ 0.02) had a higher risk of being
rapid progressors (i.e., annualized progression rate
of Vpeak $0.20 m/s/year) (Table 2). On multivariable
analysis, patients in the top Lp(a) tertile (OR: 2.6;
FIGURE 1 Calciﬁc Aortic Valve Stenosis Progression Rate According to Plasma Levels of Lp(a) and OxPL-apoB
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124095% CI: 1.4 to 5.0; p ¼ 0.003) or OxPL-apoB (OR: 2.4;
95% CI: 1.2 to 4.6; p ¼ 0.009) remained at higher risk
of being rapid progressors (Table 2).
The analysis of annualized progression rate of
aortic valve area and the assessment of the relation-
ship between OxPL-apo(a) and AS progression rate
provided consistent results (Online Appendix).
There was a signiﬁcant interaction between patient
age and Lp(a) (p ¼ 0.04) (Figure 1C) and a trend be-
tween age and OxPL-apoB (p ¼ 0.07) (Figure 1D) for AS
progression. Among patients with age #57 years (i.e.,
median age in the whole cohort), AS progression was
2-fold faster in those in the top Lp(a) tertile compared
with the middle and bottom tertiles (þ0.26  0.32
m/s/year vs. þ0.13  0.17 m/s/year; p ¼ 0.02)
(Figure 1C); similar results were obtained comparing
the top OxPL-apoB tertile with the middle and bottom
tertiles (þ0.25  0.32 m/s/year vs. þ0.13  0.17
m/s/year; p ¼ 0.05) (Figure 1D). However, in patients
age >57 years, AS progression rate did not differ ac-
cording to Lp(a) or OxPL-apoB (Figures 1C and 1D).After similar multivariable adjustment used in the
overall group except for age and smoking history,
both top tertiles of Lp(a) (beta coefﬁcient: 0.35 
0.06; p ¼ 0.003) and OxPL-apoB (beta coefﬁcient:
0.35  0.06; p ¼ 0.002) remained independent pre-
dictors of faster AS progression rate in patients age
#57 years. Among those age #57 years, patients in the
top Lp(a) or OxPL-apoB tertiles were at higher risk of
being rapid progressors (all p # 0.01) (Table 2).
In the subset of patients age #57 years, results on
aortic valve area progression were similar to those
from Vpeak progression, and the relationship between
OxPL-apo(a) and AS progression rate were similar to
those obtained with OxPL-apoB (Online Appendix).
There was no signiﬁcant interaction between the
presence of bicuspid and tricuspid valve phenotype
and Lp(a) (p ¼ 0.61) (Online Figure 1A) or OxPL-apoB
levels (p ¼ 0.94) (Online Figure 1B).
During the follow-up, 49 AS-related events
occurred (47 AVR and 2 cardiac deaths). After
adjustment for age, sex, and baseline AS severity,
TABLE 2 Risk of Rapid Calciﬁc Aortic Valve Stenosis Progression According to Plasma Levels of Lp(a) and OxPL-apoB
Percentage of Rapid Progressors
(Annualized Vpeak $0.20 m/s/year)
Risk of Being a Rapid Progressor for Patients in Tertile 3
Univariable Risk Adjusted Risk
Tertiles 1 and 2 Tertile 3
OR
(95% CI) p Value
OR
(95% CI) p Value
Overall group (n ¼ 220)
Lp(a) 36.0 55.0 2.1 (1.2–3.8) 0.009 2.6* (1.4–5.0) 0.003
OxPL-apoB 37.0 53.0 2.0 (1.2–4.6) 0.02 2.4* (1.2–4.6) 0.009
Patients age #57 yrs (n ¼ 108)
Lp(a) 23.0 54.0 4.0 (1.7–9.5) 0.001 4.9† (1.8–13.7) 0.002
OxPL-apoB 24.0 51.0 3.4 (1.4–7.8) 0.005 4.1† (1.4–11.9) 0.01
Rapid progressor patients are deﬁned by the annualized progression of Vpeak $0.20 m/s/year. *Multivariable adjustment for age, sex, hypertension, metabolic syndrome, statin
use, corrected LDL-C, creatinine, bicuspid aortic valve phenotype, aortic valve calciﬁcation score, and baseline Vpeak. †Multivariable adjustment for sex, hypertension, metabolic
syndrome, statin use, corrected LDL-C, aortic valve calciﬁcation score, and baseline Vpeak.
CI ¼ conﬁdence interval; OR ¼ odds ratio; Vpeak ¼ peak aortic jet velocity; other abbreviations as in Table 1.
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1241patients in the top Lp(a) tertile (hazard ratio: 2.0;
95% CI: 1.1 to 3.7; p ¼ 0.02) (Figures 2A and 2B) or the
top OxPL-apoB tertile (hazard ratio: 1.9; 95% CI: 1.0 to
3.4; p ¼ 0.04) (Figures 2C and 2D) had a signiﬁcantly
higher rate of clinical events. A slightly stronger as-
sociation was observed in the subset of patients age
#57 years (19 AS-related events) (Figures 2E to 2H).
EFFECT OF ROSUVASTATIN THERAPY. There was
no signiﬁcant interaction between randomization
status and Lp(a) or OxPL-apoB (p > 0.05) (Online
Figures 1C and 1D) for AS progression rate. From
baseline to 1-year post-randomization, Lp(a) and
OxPL-apoB plasma levels increased signiﬁcantly
(þ20% and þ46%, respectively; p < 0.05) in patients
treated with rosuvastatin, whereas they did not
change in patients on placebo (þ3% and þ13%,
respectively) (Figures 3A and 3B). OxPL-apoB levels
were signiﬁcantly higher at 1 year in the rosuvastatin
arm compared with placebo (Figure 3B).
DISCUSSION
This ASTRONOMER trial analysis demonstrates for
the ﬁrst time that elevated OxPL-apoB and Lp(a)
levels are independently associated with an increased
risk of echocardiographically determined AS pro-
gression rate. Furthermore, this faster progression
rate translated to a higher need for AVR, which was
accentuated in younger patients with elevated OxPL-
apoB or Lp(a) levels. The risk of Lp(a) as an inde-
pendent predictor of the progression of AS could be
explained by OxPL-apoB (or OxPL-apo[a]) levels,
which primarily reﬂect the content of OxPL on Lp(a)
present in both the lipid phase of Lp(a) and covalently
bound to the apoA moiety (9,10). These ﬁndings
support the hypothesis that AS progression and needfor AVR are mediated by the OxPL content of Lp(a),
and provide a rationale for randomized clinical trials
of Lp(a)- and OxPL-apoB-lowering therapies (28) in
patients with AS (Central Illustration).
Recent studies reported that genetically elevated
plasma levels of Lp(a) are associated with the pres-
ence of AS in the general population (4,6,7,21). Tha-
nassoulis et al. (4) reported that genetic variation in
the LPA locus (rs10455872) is associated with aortic
valve calciﬁcation and with incident AS across mul-
tiple ethnic groups. In the EPIC (European Prospec-
tive Investigation into Cancer)-Norfolk population
study, subjects who carried the rs10455872 and with
Lp(a) levels >50 mg/dl were at increased risk for AS
(6). In the Copenhagen City Heart Study and the
Copenhagen General Population Study, elevated
Lp(a) levels and corresponding genotypes were
associated with increased risk of AS and need for AVR
in the general population, with levels >74 mg/dl
predicting a 3-fold increased risk (7). The results of
these studies suggest that the association between
Lp(a) and AS may be causal.
None of the previous studies have examined the
association between Lp(a) levels and the progression
rate of established AS, which is a more relevant clin-
ical endpoint that tracks closely with AS symptoms
and ultimately determines the need for AVR. The
current study suggests that approximately 4 of 10
patients with AS have elevated Lp(a) levels. It further
documents that patients with elevated levels of Lp(a)
and OxPL-apoB have approximately a 2-fold risk of
being rapid progressors. Patients with rapid AS pro-
gression represent a conundrum in clinical care
because the underlying etiology of the progression is
often not clear and they require AVR sooner. This
study suggests that elevated Lp(a) and/or OxPL-apoB
FIGURE 2 Event-Free Survival as a Function of Lp(a) and OxPL-apoB Plasma Levels
Whole cohort (n = 220; 49 events)
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Univariable (A, C, E, and G) and adjusted (B, D, F, and H) Kaplan-Meier curves show the composite endpoint of aortic valve replacement or cardiac death comparing
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FIGURE 3 Change in Lp(a) and OxPL-apoB Plasma Levels
From Baseline to 1 Year Post-Randomization
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tients randomized to statin versus those randomized to placebo
during the ﬁrst year of the study (i.e., from baseline to 1 year).
p values are for the 2-way ANOVAs. *p < 0.05 compared to
baseline; †p < 0.05 compared to placebo. Error bars represent
the SEM. ANOVA ¼ analysis of variance; other abbreviations
as in Figure 1.
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1243levels may be key contributors to the mechanism of
rapid AS progression.
Basic investigations have also provided supporting
evidence of a role of lipoprotein disorders, oxidation,
and inﬂammation in AS (29). Oxidized LDL, which is
highly enriched in OxPL (30,31), has been implicated
in promoting valvular inﬂammation, ectopic calciﬁ-
cation, and bone formation (20), features that are
pronounced in severe AS.
Lp(a) binds OxPL (32), and much of the cardiovas-
cular disease risk and events associated with Lp(a)
can be explained by its associated OxPL (13,32,33). In
some studies, OxPL-apoB has been additive or supe-
rior to Lp(a) to predicting angiographically deter-
mined coronary artery disease (34) or cardiovascular
events (13,33). OxPL are a substrate for Lp-PLA2 to
produce LPC, which is highly expressed in the aortic
valve and promotes valve mineralization (18). Blood
Lp-PLA2 activity is associated with a faster stenosis
progression rate in the subset of patients with mild AS
(19). Finally, it has been shown that OxPL-apoB and
Lp-PLA2 potentiate risk of cardiovascular disease
events when combined in risk models (35) and that
the risk of Lp(a) and OxPL-apoB in mediating angio-
graphically determined coronary artery disease and
events was conditional on the presence of a highly
inﬂammatory interleukin-1 genotype (13). Whether
this interaction also plays a role in AS remains to be
determined.
The interaction between age and Lp(a) levels
observed in the present study was potent, suggesting
approximately 4-fold faster AS progression rate in
patients age #57 years. This suggests that the patho-
physiological mechanisms leading to the develop-
ment and progression of AS may be explained in
part by the fact that, like most genetic risk factors,
patients have elevated Lp(a) starting at birth and
this manifests in disease earlier in life. The changes in
the valves consequent to the changes induced by
OxPL lead to calciﬁcation and other pathological
changes, which dominate the natural history early
in life. As patients age, other risk factors add to the
risk of Lp(a) and OxPL-apoB; consequently, they may
lose some of their independent predictive value.
Additionally, other mechanisms may be involved
in the older population, including increased dysre-
gulation in mineral metabolism, post-menopausal
deﬁciency in estrogen, and other aging processes
(36,37).
Although data from certain animal models, Men-
delian randomization, and retrospective clinical
studies suggest that LDL-C could be an important
initiator of AS, randomized clinical trials failed to
demonstrate any signiﬁcant beneﬁt of aggressiveLDL-C-lowering therapy with statins in patients with
mild-to-moderate AS. This lack of efﬁcacy of statins
in AS could be related to the fact that these trials
only targeted older, normocholesterolemic patients
and/or that the beneﬁcial effects of statins on ste-
nosis progression rate were counterbalanced by side
effects including: 1) worsening of insulin resistance
and LDL particle phenotype as previously reported
in a post-hoc analysis of the ASTRONOMER trial (23);
2) promotion of an osteogenic phenotype by statins
(38–40); and 3) increased circulating levels of
Lp(a) and OxPL-apoB as documented in the present
and previous studies (25). Several hypotheses have
CENTRAL ILLUSTRATION Relationship of Lp(a) and OxPL With the Development and Progression of Calciﬁc Aortic Valve Stenosis
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Elevated Lp(a) and OxPL plasma levels affect clinical progression of aortic valve disease. Patients with high Lp(a) and OxPL plasma levels have a signiﬁcantly faster
calciﬁc aortic valve stenosis progression rate, represented by higher peak aortic jet velocity and larger valvular calciﬁcation, compared with those with low Lp(a)
and OxPL plasma levels. Lp(a) ¼ lipoprotein(a); OxPL ¼ oxidized phospholipids.
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between statins and increased circulating levels of
Lp(a) or OxPL-apoB plasma levels (25). However,
further studies are needed to conﬁrm the mecha-
nism underlying this association and its clinical
relevance.
CLINICAL IMPLICATIONS. It is well appreciated that
the rate of AS progression is a primary determinant of
developing symptoms of severe stenosis and the
need for AVR (29,41). From a clinical standpoint, the
most important and urgent need is to develop a
pharmacotherapy that is efﬁcient to slow or block theprogression of AS in patients who already have the
disease. By demonstrating that elevated Lp(a) and
OxPL-apoB levels are associated with a faster stenosis
progression, the present study provides an important
proof of concept for the design of randomized trials
to evaluate novel Lp(a)-lowering strategies in AS (28).
Circulating Lp(a) levels are genetically determined,
and niacin, mipomersen, or experimental drugs
only achieve a 20.0% to 40.0% reduction in Lp(a)
and also affect other lipoproteins that would con-
found clinical trial interpretation. Antisense oligo-
nucleotides targeting Lp(a) are currently in phase II
trials and have been shown to reduce Lp(a) by a
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Plasma levels of
Lp(a) and OxPL are associated with more rapid hemodynamic
progression of valvular AS and associated clinical events,
particularly in younger patients.
TRANSLATIONAL OUTLOOK: Randomized trials are needed
to evaluate the efﬁcacy of therapies that lower Lp(a) and/or
OxPL-apoB on the progression of AS and need for valve
replacement.
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1245mean of 78.0% and OxPL-apoB and OxPL-apo(a)
levels by a similar amount without affecting other
lipoproteins (42). In light of the results of the present
study and of previous studies (19), the success of
future Lp(a) and/or OxPL-apoB-lowering trials may
be increased if younger patients with mild AS are
targeted.
STUDY LIMITATIONS. The relatively small number of
patients in each subgroup raises the potential risk of
type I statistical error. The ASTRONOMER trial was
not powered to assess clinical events, such as AVR
and death. Furthermore, the top tertiles of Lp(a) or
OxPL-apoB were associated with the composite of
AVR or cardiac death only after adjusting for baseline
AS severity. Hence, these results should only be
considered hypothesis-generating pending a larger
analysis. The association between statin treatment
and increased level of Lp(a) should be interpreted
with caution given that this is a post-hoc analysis and
that there was no signiﬁcant interaction between
Lp(a) or OxPL-apoB plasma levels and statin for AS
progression. However, our ﬁndings are consistent
with previous studies that also reported an associa-
tion between statins and increased levels of Lp(a) and
OxPL-apoB (25). The clinical relevance and potential
mechanisms to explain these ﬁndings are not eluci-
dated and need to be addressed in further clinical
studies.
CONCLUSIONS
Elevated Lp(a) and OxPL-apoB plasma levels are
associated with faster AS progression rate and need
for AVR; this association was accentuated in youngerpatients. This study provides a strong rationale to test
Lp(a)-lowering and/or OxPL-apoB-lowering therapies
for reducing AS progression and the need for AVR.
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